(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 31.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.4%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.2%.
Tg Therapeutics's revenue in 2026 is $700,349,000.On average, 10 Wall Street analysts forecast TGTX's revenue for 2026 to be $147,124,036,231, with the lowest TGTX revenue forecast at $138,470,221,453, and the highest TGTX revenue forecast at $155,073,666,540. On average, 10 Wall Street analysts forecast TGTX's revenue for 2027 to be $194,875,397,340, with the lowest TGTX revenue forecast at $159,819,257,520, and the highest TGTX revenue forecast at $221,511,940,260.
In 2028, TGTX is forecast to generate $245,546,062,320 in revenue, with the lowest revenue forecast at $198,549,403,260 and the highest revenue forecast at $294,838,975,080.